Eatontown, NJ, September, 28 2015. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Calcium Acetate 667mg immediate-release capsules. This launch adds to Avet’s robust portfolio of generic oral solid products. Calcium Acetate is the AB rated generic equivalent to the phosphate binding drug PhosLo®*. It is indicated to reduce serum phosphorus in patients with end stage renal disease. According to IMS data for the twelve-months ended July 2015, the U.S. market for Calcium Acetate 667mg immediate-release capsules is approximately $45 million.